Latest filingOct 07, 2026Most recent Form 4
AGMB
AgomAb Therapeutics NV
Insider activity for last month from 09/07 to 10/07. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$266k7 buys
Total selling$00 sells
Net open-market+$266k3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly purchases, sales and code-A awards Buys Sells Awards / grants (A)
Code A includes awards, grants and other acquisitions; these are not open-market buys.
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Sep 2026Oct 2026
Top insiders
By absolute net value across the selected period- KJ+$94.4k
- ER+$86.3k
- KV+$85.9k
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period7transactionstxns
- P · Open-market buys · dominant7 · 100%
Activity by reported role
A joint filing can contribute to multiple roles7transactionstxns
- Chief financial officer · dominant3 · 43%
- Chief executive officer2 · 29%
- Director2 · 29%
Reported Holdings After
Separated by insider, security, and ownership type
Kemula Pierre Thadee VictorCommon shares · Direct
10,000Oct 06, 2026
Knotnerus Tim JasperCommon shares · Direct
21,823Oct 06, 2026
Epstein David RCommon shares · Direct
10,000Oct 06, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redSep 07 → Oct 07
LessMore
Filing-only signals
Deterministic matches in the selected period
AGMB transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #239800 | AGMB | Epstein David R | DIR | buy | 5.00k | $43.5k | P | 10/07 | 10/06 |
| #239799 | AGMB | Epstein David R | DIR | buy | 5.00k | $42.8k | P | 10/07 | 10/05 |
| #239795 | AGMB | Kemula Pierre Thadee Victor | CFO | buy | 2.00k | $17.0k | P | 10/07 | 10/06 |
| #239794 | AGMB | Kemula Pierre Thadee Victor | CFO | buy | 5.00k | $42.8k | P | 10/07 | 10/06 |
| #239793 | AGMB | Kemula Pierre Thadee Victor | CFO | buy | 3.00k | $26.0k | P | 10/07 | 10/06 |
| #239792 | AGMB | Knotnerus Tim Jasper | CEO | buy | 5.00k | $43.5k | P | 10/07 | 10/06 |
| #239791 | AGMB | Knotnerus Tim Jasper | CEO | buy | 6.00k | $50.8k | P | 10/07 | 10/05 |
AgomAb Therapeutics NV Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at AgomAb Therapeutics NV?
Epstein David R, Kemula Pierre Thadee Victor, Knotnerus Tim Jasper.
When was the latest reported open-market purchase?
Epstein David R reported a buy on Oct 06, 2026 valued at $43.5k. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $266,670.00. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.